|
|
A development stage company focused on investing and commercializing novel technology platforms concerning the life sciences sector.
Web Address |
|
Phone |
+30 6977243620 |
FAX |
41-22-71-65-319 |
Contact |
Dr. Manos Topoglidis CTO/DIR |
See Also: Biotechnology Page
Other Company Info: Goldmood Company Index
Other Company Info: Main Menu
|
||||||
| Yahoo | Quote | Fool | MSN | Nasdaq | OTC | Reuters |
| ClearStation | MarketWatch | Stockhouse | Edgar | TSX | SEC | |
For the nine months ended 30 September 2006, Acrongenomics Inc. reported no revenues. Net loss from continuing operations decreased 18% to $2.9M. Revenue reflects that the Company being in the development stage of opeations. Lower loss reflects decrease in bank charges, lowerresearch & development expenses, decrease in consulting fees, increase in interest income and the absence of amortization of patents.
